Evidence map›Paper›PMID 33728391›Full record

ReviewAPL bioengineering2021

Complex 3D bioprinting methods.

Shen Ji, Murat Guvendiren

Abstract readReview
In one paragraph

Review in APL bioengineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Droplet-based bioprinting.Nature reviews. Methods primers · 2025
    Article
  6. Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.Biomedical materials & devices (New York, N.Y.) · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Bioprinting of Cardiac Tissue in Space: Where Are We?Advanced healthcare materials · 2023
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Bioinks adapted forRSC advances · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shen JiOtto H. York Chemical and Materials Engineering, New Jersey Institute of Technology, 161 Warren Street, 150 Tiernan Hall, Newark, New Jersey 07102, USA.ORCID https://orcid.org/0000-0003-4767-7687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

3D bioprinting technology is evolving in complexity to enable human-scale, high-resolution, and multi-cellular constructs to better mimic the native tissue microenvironment. The ultimate goal is to achieve necessary complexity in the bioprinting process to biomanufacture fully-functional tissues and organs to address organ shortage and lack of patient-specific disease models. In this Review, we presented an in-depth overview of complex 3D bioprinting approaches including evolution of complex bioprinting, from simple gel-casting approach to multi-material bioprinting to omnidirectional bioprinting approaches, and emerging bioprinting approaches, including 4D bioprinting and

Identifiers

PMID33728391
PMCPMC7954578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.